Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M

Evofem Biosciences, Inc.

Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
Income from operations of $3.4M in FY2025 vs loss of $7.7M in FY2024; net income of $0.3M vs net loss of $9.0M.
Reduced total operating expenses by 38% to $16.8M, including gains from vendor settlement and royalty liability change.
Q4 2025 net sales of $9.6M (+35% YoY); operating income of $3.3M vs loss of $1.0M; net income of $2.8M vs loss of $3.0M.
Since Oct 2025: targeting 55-60% manufacturing cost reduction for PHEXX and SOLOSEC; UAE pricing certificates received.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evofem Biosciences, Inc. reported the three months ended December 31, 2025 results: revenue $9.6 million, net income $2.8 million, EPS $0.02 per basic and $0.00 per diluted share.

Period: the three months ended December 31, 2025
Revenue: $9.6 million
Net income: $2.8 million
EPS: $0.02 per basic and $0.00 per diluted share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2025, net sales were $9.6 million, versus $7.1 million in the prior year period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evofem Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $20.2 million, net income $0.3 million, EPS $0.00 per basic and diluted share.

Period: the year ended December 31, 2025
Revenue: $20.2 million
Net income: $0.3 million
EPS: $0.00 per basic and diluted share
Result: reported results

Exact text from the filing

or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include: ● Achieved record net sales of $20.2 million in 2025 — Evofem’s fifth consecutive year of net sales growth — mainly driven by sales of PHEXX® (lactic acid, citric acid, and potassium bitartrate), our hormone-free, on

View on SEC.gov

Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.